Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RVMD
- Price
- 39.66
- Stock movement up
- +0.32 (0.89%)
- Company name
- Revolution Medicines Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 6.82B
- Ent value
- 6.81B
- Price/Sales
- 9190.45
- Price/Book
- 4.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.41%
- 1 year return
- -16.43%
- 3 year return
- 11.95%
- 5 year return
- 7.65%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RVMD does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9190.45 |
| Price to Book | 4.35 |
| EV to Sales | 9184.30 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 186.93M |
| EPS (TTM) | -3.40 |
| FCF per share (TTM) | -3.30 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 742.00K |
| Gross profit (TTM) | -132.91M |
| Operating income (TTM) | -653.20M |
| Net income (TTM) | -567.06M |
| EPS (TTM) | -3.40 |
| EPS (1y forward) | -5.76 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -17912.67% |
| Operating margin (TTM) | -88031.94% |
| Profit margin (TTM) | -76423.32% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 201.26M |
| Net receivables | 0.00 |
| Total current assets | 1.58B |
| Goodwill | 14.61M |
| Intangible assets | 56.94M |
| Property, plant and equipment | 120.83M |
| Total assets | 1.76B |
| Accounts payable | 24.46M |
| Short/Current long term debt | 86.71M |
| Total current liabilities | 110.86M |
| Total liabilities | 196.69M |
| Shareholder's equity | 1.57B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -539.71M |
| Capital expenditures (TTM) | 11.40M |
| Free cash flow (TTM) | -551.11M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -36.20% |
| Return on Assets | -32.16% |
| Return on Invested Capital | -36.01% |
| Cash Return on Invested Capital | -35.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 35.99 |
| Daily high | 36.55 |
| Daily low | 35.42 |
| Daily Volume | 1.96M |
| All-time high | 60.60 |
| 1y analyst estimate | 72.40 |
| Beta | 1.16 |
| EPS (TTM) | -3.40 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| RVMD | S&P500 | |
| Current price drop from All-time high | -39.80% | -1.46% |
| Highest price drop | -73.29% | -56.47% |
| Date of highest drop | 12 May 2022 | 9 Mar 2009 |
| Avg drop from high | -39.06% | -10.99% |
| Avg time to new high | 46 days | 12 days |
| Max time to new high | 940 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
6.82B
Marketcap category
Mid-cap
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Employees
700
Website
Investor relations
-
SEC filings
CEO
Mark A. Goldsmith
Country
USA
City
Redwood City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page